



HEALTHCARE

## **Pharmaceutical Innovation**

An analysis of leading companies and strategies

By Steven Seget

 [Table of Contents](#)

## **Steven Seget**

Steven Seget is the Director of Delphi Pharma, and provides independent strategic consulting services to the pharmaceutical and biotechnology industries. Steven previously managed the strategic healthcare consulting function at Datamonitor and graduated from the London School of Economics in Accounting & Finance. [sseget@delphipharma.com](mailto:sseget@delphipharma.com)

Delphi Pharma provides strategic, financial and market-based solutions to clients, focusing primarily on the business development and licensing functions. Delphi Pharma combines an extensive research network, applied analytical expertise and an established track record to deliver high value results and measurable impact to its clients. [www.delphipharma.com](http://www.delphipharma.com)

Copyright © 2002 Business Insights Ltd  
This Management Report is published by Business Insights Ltd. All rights reserved. Reproduction or redistribution of this Management Report in any form for any purpose is expressly prohibited without the prior consent of Business Insights Ltd.

The views expressed in this Management Report are those of the publisher, not of Business Insights. Business Insights Ltd accepts no liability for the accuracy or completeness of the information, advice or comment contained in this Management Report nor for any actions taken in reliance thereon.

While information, advice or comment is believed to be correct at the time of publication, no responsibility can be accepted by Business Insights Ltd for its completeness or accuracy.

# Table of Contents

## Pharmaceutical Innovation

### *An analysis of leading companies and strategies*

<b>Executive Summary</b>	<b>10</b>	
<b>The Innovation Revolution</b>	<b>10</b>	
<b>Defining and Measuring Innovation</b>	<b>11</b>	
<b>Benchmarking Innovation</b>	<b>12</b>	
<b>Innovation Leaders</b>	<b>13</b>	
<b>Drivers of Innovation</b>	<b>14</b>	
<b>Innovation Strategy</b>	<b>15</b>	
<b>Chapter 1</b>	<b>The Innovation Revolution</b>	<b>18</b>
<b>Summary</b>		<b>18</b>
<b>Introduction</b>		<b>19</b>
<b>Reshaping the value chain</b>		<b>19</b>
Advancement in biotechnology		21
Impact		23
Decoding of the human genome		25
Impact		28
Unprecedented M&A activity		30
Impact		33
<b>The expectations gap</b>		<b>34</b>
Premium shareholder returns		35
Rising R&D costs		36
Declining R&D productivity		37
<b>A new paradigm</b>		<b>41</b>
Capturing sustainable value		44
Innovation assets		44
Competing through innovation		45

## **Chapter 2                    Defining and Measuring Innovation                    48**

<b>Summary</b>	<b>48</b>
<b>Introduction</b>	<b>49</b>
<b>Defining innovation</b>	<b>49</b>
Sustained competitive positions	49
Innovation assets	50
Pharmaceutical patents	50
<b>Measuring innovation</b>	<b>51</b>
Common measures of innovation	52
Capturing value from innovation	53
Patent generation	53
<b>The Innovation Index</b>	<b>54</b>
Framework and sources	54
Inputs and outputs	54
Relative effectiveness	55

## **Chapter 3                    Benchmarking Innovation                    58**

<b>Summary</b>	<b>58</b>
<b>Introduction</b>	<b>59</b>
<b>Innovation Index</b>	<b>59</b>
Company performance	60
Correlation with R&D investment	61
Correlation with company focus	62
<b>Quality versus quantity</b>	<b>64</b>
Innovative quality pioneers	64
Correlation with research investment	67
Correlation with Innovation Index score	68
<b>Industry innovation</b>	<b>69</b>
Relative industry performance	69
Geographical trends	70
Patent focus trends	71

## **Chapter 4                    Innovation Leaders                    74**

<b>Summary</b>	<b>74</b>
<b>Introduction</b>	<b>75</b>
<b>Innovation pioneers</b>	<b>75</b>
Innovation scorecard	75

Innovation activities and strategies	76
Case study selection	76
<b>Innovation leaders: quantity measure</b>	<b>76</b>
Immunex	77
Performance	79
Key activities and strategies	81
Novo Nordisk	85
Performance	87
Key activities and strategies	88
Genentech	92
Performance	93
Key activities and strategies	95
Takeda	98
Performance	99
Key activities and strategies	101
Merck & Co	107
Performance	108
Key activities and strategies	110
<b>Innovation leaders: quality measure</b>	<b>117</b>
Pfizer	118
Performance	119
Key activities and strategies	122
GlaxoSmithKline	130
Performance	131
Key activities and strategies	132
Novartis	143
Performance	144
Key activities and strategies	148

## **Chapter 5                      Drivers of Innovation                      156**

<b>Summary</b>	<b>156</b>
<b>Introduction</b>	<b>157</b>
<b>Technology-based drivers</b>	<b>157</b>
Integrating novel drug discovery technologies	157
Applying eR&D solutions	159
Utilizing genomics-based technologies	161
<b>Alliance-based drivers</b>	<b>163</b>
Leveraging consortia data processing	163
Accessing new technologies through alliances	164
Creating a virtual organization	165
<b>Organization-based drivers</b>	<b>166</b>
Effective knowledge management	166
Integrating functional and therapeutic expertise	167
Fostering entrepreneurial motivation in research and discovery	169

## **Chapter 6                    Innovation Strategy                    172**

<b>Summary</b>	<b>172</b>
<b>Introduction</b>	<b>173</b>
<b>The new paradigm</b>	<b>173</b>
The innovation revolution	173
Operational effectiveness	174
Strategic positioning	175
<b>The pharmaceutical innovator</b>	<b>177</b>
Competing through innovation	177
Organizational structure	177
Management issues	180
<b>Innovation strategy</b>	<b>183</b>
Innovation assets	183
Creating value	184
Capturing value	184

## **Chapter 7                    Appendix                    188**

<b>Innovation Index results</b>	<b>188</b>
<b>Glossary</b>	<b>190</b>
<b>Sources list</b>	<b>192</b>
<b>Index</b>	<b>197</b>

# List of Figures

Figure 1.1:	The reconfigured pharmaceutical value chain	20
Figure 1.2:	Biotechnology product launches, 1991—2000	22
Figure 1.3:	Biotechnology alliances, 1996—2000	24
Figure 1.4:	Genomics-related licensing activity, 1996—2001	29
Figure 1.5:	Pharmacia Corporation's M&A history, 1990—2000	31
Figure 1.6:	Aventis AG's M&A history, 1990—2000	32
Figure 1.7:	GlaxoSmithKline's M&A history, 1990—2000	32
Figure 1.8:	Cost of new drug approvals, 1991—2001	39
Figure 1.9:	R&D productivity, 1980—2001	40
Figure 1.10:	Forecast R&D productivity, 2000—2050	41
Figure 1.11:	The emerging paradigm	43
Figure 3.12:	Innovation Index – R&D trends, 2000—2001	62
Figure 3.13:	Innovation Index – Company focus, 2000—2001	63
Figure 3.14:	Top selling drugs by company, 2000	65
Figure 3.15:	New drug approvals by company, 2000—2001	66
Figure 3.16:	Innovation quality – R&D spend, 2000—2001	67
Figure 3.17:	Innovation quality – R&D as % sales, 2000—2001	68
Figure 3.18:	Innovation quality – Innovation Index, 2000—2001	69
Figure 6.19:	Mintzberg's taxonomy of organizational forms	178

# List of Tables

Table 1.1:	Biotechnology product launches, 1991—2000	22
Table 1.2:	Biotechnology alliances, 1996—2000	24
Table 1.3:	Results of major collaborations with genomics companies, 2001	27
Table 1.4:	Cost of new drug approvals, 1991—2001	38
Table 1.5:	R&D productivity, 1980—2001	39
Table 3.6:	Innovation Index, 2000—2001	60
Table 3.7:	Cross industry Innovation Index score, 2000—2001	70
Table 4.8:	Immunex: innovation scorecard, 2000—2001	78
Table 4.9:	Novo Nordisk: innovation scorecard, 2000—2001	86
Table 4.10:	Genentech: innovation scorecard, 2000—2001	93
Table 4.11:	Takeda: innovation scorecard, 2000—2001	99
Table 4.12:	Merck & Co: innovation scorecard, 2000—2001	107
Table 4.13:	Pfizer: innovation scorecard, 2000—2001	119
Table 4.14:	GlaxoSmithKline: innovation scorecard, 2000—2001	131
Table 4.15:	Novartis: innovation scorecard, 2000—2001	144
Table 4.16:	Novartis' key R&D alliances and partnerships, 2001	149
Table 7.17:	Innovation Index: top 40 leading companies, 2000—2001	188
Table 7.18:	Innovation Index: top 40 leading companies, 2000—2001 (cont'd)	189